Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | NAMPT | P43490 | 8/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16639787 | 0.90 | SMN1; SMN2 (0.55) | KDM4EALDH1A1SMN1; SMN2NAMPTLMNA | |
| SCHEMBL22166400 | 0.84 | KDM4E (0.55) | KDM4EALDH1A1SMN1; SMN2NAMPTLMNA | |
| SCHEMBL27312618 | 0.78 | ALDH1A1 (0.88) | KDM4EALDH1A1NAMPTLMNAGAA | |
| SCHEMBL16639777 | 0.78 | THRB (0.54) | KDM4EALDH1A1NAMPTLMNAMAPT | |
| SCHEMBL16639770 | 0.76 | SENP1 (0.61) | KDM4ESMN1; SMN2NAMPTLMNAMAPT | |
| SCHEMBL16639769 | 0.76 | NAMPT (0.51) | KDM4EALDH1A1NAMPTLMNAMAPT | |
| SCHEMBL31562927 | 0.75 | NAMPT (0.75) | ALDH1A1NAMPT | |
| SCHEMBL16639755 | 0.74 | CHRM4 (0.52) | KDM4EALDH1A1NAMPTLMNAMAPT | |
| SCHEMBL16644246 | 0.74 | TP53 (0.74) | ALDH1A1SMN1; SMN2MAPTKMT2AGAA | |
| SCHEMBL16644162 | 0.73 | TP53 (0.72) | ALDH1A1SMN1; SMN2MAPTKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696692-B2 | Amido-benzyl sulfone and sulfoxide derivates | Valo Health, LLC | 2020-06-30 | — | — | US | disclosed |
| US-20150104384-A1 | AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES | VALO HEALTH, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150104384-A1 | AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES | VALO HEALTH, INC. | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696692-B2 | Amido-benzyl sulfone and sulfoxide derivates | STS, SQOR, SULT1E1 | KDM4E 594/4885ALDH1A1 2853/4885SMN1; SMN2 346/4885 |
| US-20150104384-A1 | AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES | STS, SULT1E1, CBS | KDM4E 661/4885ALDH1A1 2737/4885SMN1; SMN2 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.